JP2005500345A - ５−ｈｔ６受容体親和性を有する５−アリールスルホニルインドール - Google Patents

５−ｈｔ６受容体親和性を有する５−アリールスルホニルインドール Download PDF

Info

Publication number
JP2005500345A
JP2005500345A JP2003516514A JP2003516514A JP2005500345A JP 2005500345 A JP2005500345 A JP 2005500345A JP 2003516514 A JP2003516514 A JP 2003516514A JP 2003516514 A JP2003516514 A JP 2003516514A JP 2005500345 A JP2005500345 A JP 2005500345A
Authority
JP
Japan
Prior art keywords
indol
alkyl
sulfonyl
dimethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003516514A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005500345A5 (enExample
Inventor
ジャン−ミン・フ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of JP2005500345A publication Critical patent/JP2005500345A/ja
Publication of JP2005500345A5 publication Critical patent/JP2005500345A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003516514A 2001-08-03 2002-08-01 ５−ｈｔ６受容体親和性を有する５−アリールスルホニルインドール Pending JP2005500345A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30983201P 2001-08-03 2001-08-03
US32688501P 2001-10-03 2001-10-03
PCT/US2002/024759 WO2003011284A1 (en) 2001-08-03 2002-08-01 5-arylsulfonyl indoles having 5-ht6 receptor affinity

Publications (2)

Publication Number Publication Date
JP2005500345A true JP2005500345A (ja) 2005-01-06
JP2005500345A5 JP2005500345A5 (enExample) 2005-09-29

Family

ID=26977033

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003516514A Pending JP2005500345A (ja) 2001-08-03 2002-08-01 ５−ｈｔ６受容体親和性を有する５−アリールスルホニルインドール

Country Status (7)

Country Link
US (1) US6565829B2 (enExample)
EP (1) EP1411925A1 (enExample)
JP (1) JP2005500345A (enExample)
BR (1) BR0211561A (enExample)
CA (1) CA2452743A1 (enExample)
MX (1) MXPA04001089A (enExample)
WO (1) WO2003011284A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008524275A (ja) * 2004-12-21 2008-07-10 エフ．ホフマン−ラ ロシュ アーゲー クロマン誘導体及び５−ｈｔレセプターリガンドとしてのそれらの使用
JP2009504633A (ja) * 2005-08-12 2009-02-05 スヴェン・ライフ・サイエンシズ・リミテッド 機能性５−ｈｔ６リガンドとしてのアミノアリールスルホンアミド誘導体
JP2009514828A (ja) * 2005-11-03 2009-04-09 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ６阻害剤としてのアリールスルホニルクロマン類、タンパク質キナーゼ阻害剤としてのインドリルマレイミド誘導体
JP2009541423A (ja) * 2006-06-23 2009-11-26 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ コリンエステラーゼ阻害剤と５‐ｈｔ６レセプター親和性の化合物との組合せ
JP2009541249A (ja) * 2006-06-20 2009-11-26 エフ．ホフマン−ラ ロシュ アーゲー アリールスルホニルナフタレン誘導体およびその使用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE398108T1 (de) 2002-03-27 2008-07-15 Glaxo Group Ltd Chinolinderivate und deren verwendung als 5-ht6 liganden
CA2521177C (en) * 2003-04-25 2012-12-04 Allergan, Inc. Use of a botulinum neurotoxin to alleviate various disorders
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
DE602004016491D1 (de) * 2003-05-09 2008-10-23 Esteve Labor Dr Verwendung von sulfonamid-derivate zur herstellung eines medikaments für die vorbeugung oder behandlung von essstörungen
HRP20060100T3 (en) 2003-07-22 2007-03-31 Arena Pharmaceuticals Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
DE102004048716A1 (de) * 2004-10-06 2006-04-20 Dr. Willmar Schwabe Gmbh & Co. Kg Verwendung von Lavendelöl zur Prophylaxe und Behandlung von Neurasthenie, Somatisierungsstörungen und von anderen stress-assoziierten Erkrankungen
GB0422263D0 (en) * 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds
BRPI0515835A (pt) * 2004-12-21 2008-08-12 Hoffmann La Roche derivados de tetralina e de indano e seus usos
DK1831159T3 (da) * 2004-12-21 2010-03-22 Hoffmann La Roche Tetralin og indanderivater samt anvendelser deraf
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
WO2009082268A2 (ru) 2007-12-21 2009-07-02 Alla Chem, Llc ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226532D0 (en) 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
CA2322162A1 (en) 1998-02-25 1999-09-02 Genetics Institute, Llc Inhibitors of phospholipase enzymes
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
MY122278A (en) * 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
CZ305838B6 (cs) * 2001-03-29 2016-04-06 Eli Lilly And Company N-(2-arylethyl)benzylaminy jako antagonisté receptoru 5-HT6

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008524275A (ja) * 2004-12-21 2008-07-10 エフ．ホフマン−ラ ロシュ アーゲー クロマン誘導体及び５−ｈｔレセプターリガンドとしてのそれらの使用
JP2009504633A (ja) * 2005-08-12 2009-02-05 スヴェン・ライフ・サイエンシズ・リミテッド 機能性５−ｈｔ６リガンドとしてのアミノアリールスルホンアミド誘導体
JP2009514828A (ja) * 2005-11-03 2009-04-09 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ６阻害剤としてのアリールスルホニルクロマン類、タンパク質キナーゼ阻害剤としてのインドリルマレイミド誘導体
JP2009541249A (ja) * 2006-06-20 2009-11-26 エフ．ホフマン−ラ ロシュ アーゲー アリールスルホニルナフタレン誘導体およびその使用
JP2009541423A (ja) * 2006-06-23 2009-11-26 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ コリンエステラーゼ阻害剤と５‐ｈｔ６レセプター親和性の化合物との組合せ

Also Published As

Publication number Publication date
US6565829B2 (en) 2003-05-20
US20030060498A1 (en) 2003-03-27
WO2003011284A1 (en) 2003-02-13
CA2452743A1 (en) 2003-02-13
BR0211561A (pt) 2004-11-30
MXPA04001089A (es) 2004-05-20
EP1411925A1 (en) 2004-04-28

Similar Documents

Publication Publication Date Title
US6565829B2 (en) 5-arylsulfonyl indoles useful for treating disease
US6727274B2 (en) Arylsulphonyl substituted-tetrahydro- and hexahydro-carbazoles
TW520989B (en) Pharmaceutical composition for treating dementia, dementia of the Alzheimer's type, dyskinesias and behavioral manifestations of mental retardation, conduct disorder and autistic disorder
EA018113B1 (ru) Индолы в качестве модуляторов никотинового рецептора ацетилхолина подтипа альфа-71
NO310070B1 (no) Benzo[g]kinolinderivater, fremstilling herav, farmasöytiske midler og preparater inneholdende disse samt anvendelse av derivatene for fremstilling av medikamenter
TW201018467A (en) Novel compounds as calcium channel blockers
JP2007500168A (ja) １−スルホニルインドール誘導体、それらの調製及び５−ｈｔ６リガンドとしてのそれらの使用
TW200425894A (en) Treatment of psychotic and depressive disorders
BRPI0616609A2 (pt) compostos que têm atividade no receptor m1, composição farmacêutica contendo tais compostos, processo para preparação dos mesmos, bem como seus usos em medicina
EA019486B1 (ru) Производные индол-2-она, двузамещенные в положении 3, их получение и их применение в терапии
PT1567492E (pt) N-arilsulfonil-3-aminoalcoxi-indóis
KR101997699B1 (ko) Ampa 수용체에 특이적으로 결합하는 신규 화합물
JP3057095B2 (ja) イサチン誘導体、その製造方法及びその使用方法
KR20120112726A (ko) ５?ｈｔ６ 수용체 리간드인 술폰 화합물
AU2004262486A1 (en) Indol-4 sulfonamide derivatives, their preparation and their use 5-HT-6 as modulators
TWI258480B (en) Novel piperidinecarboxamide derivatives, a method for their preparation and pharmaceutical compositions containing them
TW201206485A (en) Compounds for binding and imaging amyloid plaques and their use
JP2004508352A (ja) 置換縮合ピロールイミン及びピラゾールイミン
JP2003527377A (ja) ５−置換アリルピリミジン
TW419478B (en) 6-methoxy-1H-benzotriazol-5-carboxamide derivatives, preparation and pharmaceutical composition
AU2001292236B2 (en) 5-phenylbenzylamine compounds, process for their production and intermediates for their synthesis
JP2009500335A (ja) ヒスタミンｈ３受容体薬剤、製剤及び治療的使用
JP2010523525A (ja) 早漏症の治療のためのピリジノン誘導体
JP2004524363A (ja) ヒスタミンｈ３受容体のリガンドとして用いるに有用なイミダゾリル誘導体
JP2007500167A (ja) インドール−７−スルホンアミド誘導体、それらの調製、および５−ｈｔ−６調節剤としてのそれらの使用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090519

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091201